News items related to:
-
• Lancet publishes a review of the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic, drawing...
-
• US coronavirus cases surpass 44 million. Source • Pfizer and its partner BioNTech announce that they have asked the...
-
• Merck, which has announced that it will enter into non-exclusive voluntary licensing agreements with generics manufacturers to enable access...
-
• Moderna issues a press release announcing that the EMA has authorized a third booster dose of its coronavirus vaccine...
-
• Lancet publishes research on overall and Delta variant-specific effectiveness of the Pfizer/BioNTech coronavirus vaccine against SARS-CoV-2 and hospitalization for...
-
• BioNTech’s CEO, Ugur Sahin, suggests that a new formulation of the coronavirus vaccine it co-developed with Pfizer is likely...
-
• In the US, deaths from COVID-19 surpass 700,000. Although the country has offered widespread access to coronavirus vaccines at...
-
• Harvard University posts a pre-print article detailing costs for generic mass production of Merck’s experimental COVID-19 antiviral treatment, molnupiravir....
-
• The New York Times reports that countries in Asia, which were behind on coronavirus vaccination, are catching up to,...
-
• PLOS publishes a retrospective cohort study using electronic health records from 81 million patients including 273,618 COVID-19 survivors to...
-
• Pfizer and BioNTech submit data to the US FDA on safety and efficacy of their coronavirus vaccine in children...
-
• Reuters reports that COVAX is planning to change its vaccine allocation system after providing the UK with over half...